Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:02 AM
Ignite Modification Date:
2025-12-25 @ 2:02 AM
NCT ID:
NCT06207760
Eligibility Criteria:
Inclusion Criteria:
1. Being male or female depressed patients (aged 25-45);
2. Having a current DSM-V diagnosis of non-psychotic major depressive disorder confirmed by SCID;
3. Being non-responder to a current SSRI for at least 8 weeks, and historically to one other SSRI;
4. Being in stable antidepressant therapy for at least 8 weeks;
5. Being tolerant to the current SSRI;
6. Accepting Minocycline treatment;
7. Having CPR level\> 2 mg/L;
8. Having signed and dated an informed consent to participate in the study;
9. Having no contraindications to receive treatment with Minocycline;
10. Having no contraindications to undergo the 11C-PK PET scan.
Exclusion Criteria:
1. Having active suicidal ideation;
2. Having a primary diagnosis of bipolar disorder, obsessive-compulsive disorder, eating disorder, PTSD;
3. Having a history of substance/alcohol abuse;
4. Having received tetracycline therapy within the previous 2 months;
5. Having a history of sensitivity to this class of drugs;
6. Having acute infections or an autoimmune or inflammatory disorder;
7. Having CRP\>20 mg/L, as indicates acute infection or other major pathology;
8. Being sensitive to Minocycline;
9. Having a history of severe allergy or hypersensitivity to drugs;
10. Being hypersensitive to the active substance, to other tetracyclines or to any of the excipients;
11. Having severe renal failure;
12. Having hepatic dysfunction;
13. Being pregnant and in lactation;
14. (for MRI) Having pacemakers, electromechanical devices, ferromagnetic vascular clips, cochlear implants, stapedial prostheses, ferromagnetic foreign bodies, sickle cell anemia;
EXCLUSION CRITERIA (FOR ONLY THOSE PATIENTS WHO WILL PERFORM 11C PK PET)
15. Having undergone imaging or treatment procedures using radiopharmaceuticals 7 days prior to the imaging session of this study;
16. Being unable to complete the 11C PK PET session, according to the clinician;
17. Being in current or previous (last two months) treatment with neuroactive drugs (benzodiazepines, barbiturates, picrotoxin and muscimol);
18. Being women of childbearing potential who are not surgically sterile and who do not guarantee to abstain from sexual activity for the 24 hours following the administration of 11C PK PET.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
25 Years
Maximum Age:
45 Years
Study:
NCT06207760
Study Brief:
Protocol Section:
NCT06207760